NASDAQ · Biotechnology

Kura Oncology, Inc. (KURA) Stock

$10.60 +0.76% NASDAQ: KURA Healthcare

Valuation

MetricValue
Price$10.60
Market Cap$941.01M
P/E Ratio-3.16
P/B Ratio19.54
P/S Ratio12.24
EPS (TTM)$-3.18
52-Week High$13.90
52-Week Low$7.36
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-207.18%
ROA-50.49%
ROCE-67.74%
Gross Margin-453.73%
Operating Margin-453.73%
Net Margin-384.30%
Debt/Equity0.50
Current Ratio6.06

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$54.0M$67.0M
Operating Profit$-131.0M$-140.0M$-166.0M$-193.0M$-304.0M
Net Profit$-130.0M$-136.0M$-153.0M$-174.0M$-279.0M
EPS$-1.97$-2.03$-2.08$-2.02$-3.18
Op Margin———-358.6%-449.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$534.0M$456.0M$449.0M$760.0M$738.0M
Total Liabilities$27.0M$36.0M$52.0M$347.0M$564.0M
Cash$91.0M$52.0M$37.0M$224.0M$149.0M
Borrowings$7.0M$14.0M$17.0M$17.0M$20.0M

Latest News

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026 GlobeNewswire · Jul 14, 2026 Does Kura Oncology’s (KURA) Shift Into Russell Growth Indexes Redefine Its Core Investment Story? Simply Wall St. · Jul 7, 2026 Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 3, 2026 Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates? Insider Monkey · Jun 30, 2026 Kura Oncology, Kyowa Kirin Cancer Combo Therapy Extends Survival in AML Patients MT Newswires · Jun 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-105.0M$-110.0M$-125.0M$134.0M$-64.0M
Investing Cash Flow$-128.0M$32.0M$15.0M$-102.0M$-20.0M
Financing Cash Flow$-1.0M$4.0M$1.0M$9.0M$0
Net Cash Flow$-235.0M$-39.0M$-14.0M$187.0M$-75.0M
Free Cash Flow$-106.0M$-111.0M$-125.0M$134.0M$-71.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.08
EV / EBITDA-3.08
FCF Yield-12.42%
Quick Ratio4.71
Interest Coverage-224.01
Return 1Y62.27%
Return 3Y1.85%
Return 5Y-38.91%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BBOTBridgeBio Oncology Therapeutics, Inc. $3.31 -3.22% -0.90 $265.15M 0.00%
CRDFCardiff Oncology, Inc. $1.08 +1.89% -1.87 $83.24M 0.00%
HCMHUTCHMED (China) Limited $11.25 +0.99% 4.28 $1.96B 0.00%
NRIXNurix Therapeutics, Inc. $22.35 +0.63% -6.61 $2.32B 0.00%
ORICOric Pharmaceuticals, Inc. $11.99 -0.33% -9.25 $1.24B 0.00%

About Kura Oncology, Inc.

Kura Oncology, Inc. is led by CEO Troy Edward Wilson, employs 192 people, headquartered in US, publicly traded since 2015.

Kura Oncology, Inc. (KURA) stock trades at $10.60 with a market capitalization of $941.01M. The stock is valued at a price-to-earnings (P/E) ratio of -3.16, price-to-book of 19.54, price-to-sales of 12.24. Over the past 52 weeks the stock has ranged between $7.36 and $13.90, and currently trades 23.7% below its 52-week high.

On profitability, Kura Oncology, Inc. generates a return on equity (ROE) of -207.18%, return on capital employed of -67.74%, an operating margin of -453.73%, a net profit margin of -384.30%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides